Status:
COMPLETED
A Study of P38 Inhibitor (4) Monotherapy in Patients With Active Rheumatoid Arthritis
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This 4 arm study will compare the safety and efficacy, with regard to reduction of signs and symptoms, of P38 Inhibitor (4) (50, 150 or 300mg po qd) monotherapy versus methotrexate monotherapy in adul...
Eligibility Criteria
Inclusion
- adult patients \>18 years of age, with active RA;
- receiving treatment for RA on an outpatient basis;
- females of child-bearing potential, or nonsterilized males with partners of child-bearing potential, must use reliable contraception during, and for 4 weeks after, the study.
Exclusion
- major surgery within 8 weeks prior to screening;
- rheumatic autoimmune disease or inflammatory joint disease other than RA;
- treatment with methotrexate within 8 weeks of baseline;
- concurrent use of DMARDs, including anti-TNF or other biologic therapy for RA.
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2007
Estimated Enrollment :
204 Patients enrolled
Trial Details
Trial ID
NCT00303563
Start Date
April 1 2006
End Date
December 1 2007
Last Update
November 2 2016
Active Locations (61)
Enter a location and click search to find clinical trials sorted by distance.
1
Anniston, Alabama, United States, 36207
2
Scottsdale, Arizona, United States, 85251
3
Tucson, Arizona, United States, 85704
4
Tucson, Arizona, United States, 85712